Lacosamidum
Lacosamidum est medicamentum pharmaceuticum cum virtutibus anticonvulsivis convulsionum partialium apud adultos[1].
 |
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt. |
| Cognitores | |
|---|---|
| ChemSpider | 189902 |
| PubChem | 219078 |
| DrugBank | DB06218 |
| Natura chemica | |
| |
| |
| Formula summarum | C 13H 18N 2O 3 |
| Massa molaris | 250.294 g/mol |
| Natura pharmacologica | |
| Codex ATC | N03AX18 (WHO) |
| Semivita biologica | 13 horae |
| Metabolismus | iecore (hepaticus): Demethylatione CYP2C19, CYP2C9, CYP3A4 |
| Excretio | renibus |
| Ad usum therapeuticum | |
| Applicatio | per os, i.v. |
| MedlinePlus | a609028 (Anglice) |
Historia
recensereSubstantia primum anno 1996 in Houstonia ex N-benzyl-2-acetamidopropionamido derivatum descripta est[2].
Natura lacosamidi
recensereNatura chemica
recensereNomen IUPAC suum est (2R)-N-benzylo-2-acetamido-3-methoxy-propano-amidum, massa molaris sua 250.294 g/mol. Inest praecursor chemicus benzylamidum C
6H
5CH
2NH
2, quod est benzenum cum NH2. Pariter est derivatum aminoacidorum (—NH—CO—COOH).
Natura pharmacologica
recensereLacosamidum est medicamentum cum virtutibus anticonvulsivis. Codex ATC est N03AX18 (WHO).
Pharmacodynamica
recensereLacosamidum canales ionticos natrii tensione reclusos (VGSC) tarde inhibit[3].
Pharmacocinetica
recensereTempus semivitae biologicum [4] 13 horae sunt. Metabolismus per cytochromatum CYP2C19[5], CYP2C9, CYP3A4 fit. Excretio est per urinas.
Effectus lacosamidi
recensereEffectus adversarii
recensereLacosamidum enzyma hepatica in sanguinem liberare potest, ut valores sanguinei eorum augeantur.
Usus lacosamidi
recensereDosis diurna definita (DDD) est 300 mg per die p.o.[6]
Methodus therapeutica
recensereIn morbum comitialem tractando dosis initialis sit a 50 mg ad 100 mg die, deinde hebdomade inter 50 et 100 mg die augenti, bis distributum[7], usque a 200 mg ad 400 mg die, commendatur.
Notae
recensere- ↑ Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd G. D. (2007). "Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures". Epilepsia 48 (7): 1308-17
- ↑ Choi D., Stables J. P., Kohn H. (Apr 1996). "Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives". Journal of medicinal chemistry 39 (9): 1907-16
- ↑ Errington A. C., Stöhr T., Heers C., Lees G. (Ian 2008). "The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels". Molecular pharmacology 73 (1): 157-69
- ↑ Goldbook
- ↑ Cawello W., Mueller-Voessing C., Fichtner A. (Mai 2014). "Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial". Clinical drug investigation 34 (5): 317-25doi:10.1007/s40261-014-0177-2
- ↑ Systema classificationis Anatomicum Therapeuticum Chemicumque, cap. N03AX cum Pregabalini referentia,
- ↑ Benkert O, Hippius H (2017). Kompendium der Psychiatrischen Pharmakotherapie, Springer (Theodisce)
Nexus externi
recensere- LiverTox de lacosamido (Anglice)
- Lacosamidum et CYP2C19 (Anglice)